Identification of new antioxidant drugs in a human in vitro model of ageing‐associated cataract

Abstract

Aims/Purpose: Cataracts are a significant cause of global blindness, impacting millions (10.8 million patients), and their prevalence is expected to increase over the coming decades as our populations age. Oxidative stress disrupts ROS (reactive oxygen species) balance in lens fibre cells, leading to lens protein degradation and accumulation, developing age‐related cataracts. The lens has protective mechanisms, including high GSH levels and antioxidant enzymes like catalase, safeguarding lens health. While surgery is currently the only effective treatment, non‐invasive drug‐based approaches show potential by reducing risks and complications. With its potent antioxidant activity, resveratrol may protect lens cells and slow cataract development. However, the limited ability of resveratrol to penetrate lens tissue restricts its direct effects. Therefore, designing new molecules to improve ADME (absorption, distribution, metabolism and excretion) properties is required.Methods: In this study, we used an in vitro model of cataracts by inducing oxidative stress and cell death by adding hydrogen peroxide (H2O2) and luperox to lens epithelial cells to evaluate the protective effects of new molecules against oxidative stress and compared them with resveratrol. Our study assessed the cell viability, intracellular ROS level, mitochondrial function, catalase activity and GSH/GSSH level.Results: These compounds preserved cell viability, reduced ROS levels, maintained mitochondrial function and enhanced catalase activity and GSH levels in lens epithelial cells exposed to H2O2. The novel drugs, CAB‐C1 and CAB‐C2, demonstrated beneficial effects on cellular health.Conclusions: Developing drugs for cataract treatment enables early intervention, particularly for individuals with mild or moderate cataracts who may not require surgery yet. Such advancements might improve patients' quality of life and have implications for ocular science and age‐related eye diseases.